Japanese Medical Agency (PMDA) supports the expansion of the Phase III program for PledOx® to include Japanese patients
June 13, 2018 02:30 ET
|
PledPharma AB
Stockholm, June 13, 2018. PledPharma AB and Solasia Pharma K.K. (Solasia) today announced that the Japanese Pharmaceuticals and Medical Devices Agency, PMDA, following a meeting with PledPharma and...
Telix Pharmaceuticals Establishes Japanese Subsidiary, Appoints Key Executives
January 14, 2018 21:12 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO Japan, Jan. 15, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the...
Full Product Approval In Japan Received By Mesoblast Licensee
September 18, 2015 01:23 ET
|
Mesoblast
NEW YORK CITY and MELBOURNE, Australia, Sept. 18, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that its licensee JCR Pharmaceuticals Co. Ltd has received full...